Skip to main page content

• HOME
• Current Issue
• Archive
• Alerts
• About ASM
• Contact us
• Tech Support
• Journals.ASM.org

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zbinden, R. Articles by von Graevenitz, A. Search for Related Content PubMed PubMed Citation Articles by Zbinden, R. Articles by von Graevenitz, A.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, March 2002, p. 871-874, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.872-875.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

In Vitro Activities of BAL9141, a Novel Broad-Spectrum Pyrrolidinone Cephalosporin, against Gram-Negative Nonfermenters

R. Zbinden,^* V. Pünter, and A. von Graevenitz

Department of Medical Microbiology, University of Zurich, 8028 Zurich, Switzerland

Received 8 June 2001/ Returned for modification 18 October 2001/ Accepted 21 November 2001

Top Abstract Text References

 
The activities of BAL9141 (formerly Ro 63-9141), a novel pyrrolidinone-3-ylidenemethyl cephalosporin, against 244 strains of gram-negative nonfermenters were evaluated. The overall MIC at which 50% of isolates are inhibited (MIC₅₀) and the overall MIC₉₀ were 2 and 64 µg/ml, respectively, which are similar to those of imipenem, lower than those of the other cephalosporins tested, amoxicillin, and the ticarcillin-clavulanic acid combination, and much higher than those of ciprofloxacin. BAL9141 shows species-dependent activity in vitro against a variety of gram-negative nonfermentative pathogens.

Top Abstract Text References

 
BAL9141 (formerly Ro 63-9141) is a novel pyrrolidinone-3-ylidenemethyl cephalosporin that consistently has activity against methicillin-resistant strains of Staphylococcus spp. but that exhibits promising in vitro and in vivo activities against a variety of gram-negative pathogens (1). The purpose of this study was to evaluate the activity of BAL9141 against a broad range of aerobic gram-negative glucose-nonfermentative rods.

(Part of this work was presented at the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, Calif., 1998 [R. Zbinden, V. Puenter, and A. von Graevenitz, Abstr. 38th Intersci. Conf. Antimicrob. Agents Chemother., abstr. F-19, 1998].).

The MICs of BAL9141 and nine other antimicrobials were determined by the NCCLS agar dilution method on non-cation-adjusted Mueller-Hinton agar (Becton Dickinson Microbiology Systems, Cockeysville, Md.) for 244 gram-negative nonfermenters that were collected through 1995 in the Department of Medical Microbiology, University of Zurich, Zurich, Switzerland, and a reference strain, Pseudomonas aeruginosa ATCC 27853 (5). A 0.5 McFarland suspension in phosphate-buffered saline was diluted 1/10 to obtain the desired inoculum of 10⁷ CFU/ml. A multipoint inoculator was used to deliver 10⁴ CFU per spot to each test plate and to control plates without antibiotics. Cultures were incubated at 35°C for 20 h in an aerobic atmosphere in accordance with the NCCLS methodology (5). BAL9141 of known potency was supplied by F. Hoffmann-La Roche, Basel, Switzerland (courtesy of P. Hebeisen). The other compounds were obtained from commercial sources. Identification of the isolates studied was in accordance with recommended methods (4).

The MICs of BAL9141 and the other antimicrobial agents are shown in Table 1.

View this table: [in this window] [in a new window]

TABLE 1. Comparative in vitro activities of BAL9141 against 244 gram-negative nonfermenters

BAL9141 was particularly active against Agrobacterium radiobacter, Alcaligenes faecalis, Bordetella bronchiseptica, Moraxella spp., Ochrobactrum anthropi, Pseudomonas oryzihabitans, Ralstonia pickettii, and Weeksella virosa. The results of our study of the activities of BAL9141 against P. aeruginosa and Acinetobacter spp. were by and large in agreement with those of Hebeisen et al. (1), except that, across the board, our pathogens were more susceptible than the selected isolates used by those investigators. Our results for the other antimicrobials are in line with those obtained by Jones et al. (2), Klein et al. (3), Spangler et al. (7), and von Graevenitz and Bucher (8).

The overall activities of BAL9141 against the glucose-nonfermentative gram-negative rods tested were most similar to those of imipenem in terms of MIC₅₀s and MIC₉₀s. Imipenem, however, had clearly superior activity against Achromobacter xylosoxidans, Acinetobacter baumannii, Brevundimonas vesicularis, Burkholderia cepacia, Comamonas acidovorans, P. aeruginosa, Pseudomonas stutzeri, and W. virosa. For the other species tested, their activities were similar. Cefepime was more active against Chryseobacterium indologenes and Sphingomonas spp. and, to some extent, was also more active against P. aeruginosa. Cefozopran was, overall, as active as cefepime. With the exception of ceftazidime against B. cepacia, C. acidovorans, and P. aeruginosa, the expanded-spectrum and broad-spectrum cephalosporins were less active than BAL9141 or the penicillin-clavulanic acid combinations.

While imipenem and ciprofloxacin have greater potencies against most of the organisms tested, BAL9141, cefepime, and cefozopran, in decreasing order, appear to be potent enough to be of clinical utility against most of the species evaluated apart from Stenotrophomonas maltophilia and Chryseobacterium spp. All compounds tested were inactive against S. maltophilia and Chryseobacterium meningosepticum (the activity of ciprofloxacin was borderline).

View this table: [in this window] [in a new window]

TABLE 2. Cumulative in vitro activities of BAL9141 and comparator drugs against 244 gram-negative nonfermenters

 
We gratefully acknowledge the support of these studies by F. Hoffmann-La Roche.

We thank P. Hohl and S. Shapiro for critical reading of the manuscript.

 
* Corresponding author. Mailing address: Department of Medical Microbiology, University of Zurich, Gloriastrasse 32, 8028 Zurich, Switzerland. Phone: 41 1 634 27 00. Fax: 41 1 634 49 06. E-mail: RZbinden{at}immv.unizh.ch.

Top Abstract Text References

 

1
1. Hebeisen, P., I. Heinze-Krauss, P. Angehrn, P. Hohl, M. G. P. Page, and R. L. Then. 2001. In vitro and in vivo properties of Ro 63-9141, a novel broad-spectrum cephalosporin with activity against methicillin-resistant staphylococci. Antimicrob. Agents Chemother. 45:825-836.[Abstract/Free Full Text]
2
2. Jones, R. N., M. A. Pfaller, G. V. Doern, M. E. Erwin, R. J. Hollis, and Cefepime Study Group. 1998. Antimicrobial activity and spectrum investigation of eight broad-spectrum ß-lactam drugs: a 1997 surveillance trial in 102 medical centers in the United States. Diagn. Microbiol. Infect. Dis. 30:215-228.[CrossRef][Medline]
3
3. Klein, O., N. X. Chin, H. B. Huang, and H. C. Neu. 1994. In vitro activity of SCE-2787, a new cephalosporin with potent activity against Pseudomonas aeruginosa and members of the family Enterobacteriaceae. Antimicrob. Agents Chemother. 38:2896-2901.[Abstract/Free Full Text]
4
4. Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 1999. Manual of clinical microbiology, 7th ed. American Society for Microbiology, Washington, D.C.
5
5. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
6
6. National Committee for Clinical Laboratory Standards. 2001. Performance standards for antimicrobial susceptibility testing, 11th informational supplement. M100-S11. National Committee for Clinical Laboratory Standards, Wayne, Pa.
7
7. Spangler, S. K., M. A. Visalli, M. R. Jacobs, and P. C. Appelbaum. 1996. Susceptibilities of non-Pseudomonas aeruginosa gram-negative nonfermentative rods to ciprofloxacin, ofloxacin, levofloxacin, D-ofloxacin, sparfloxacin, ceftazidime, piperacillin, piperacillin-tazobactam, trimethoprim-sulfamethoxazole, and imipenem. Antimicrob. Agents Chemother. 40:772-775.[Abstract]
8
8. von Graevenitz, A., and C. Bucher. 1982. The effect of N-formimidoyl thienamycin, ceftazidime, cefotiam, ceftriaxone and cefotaxime on non-fermentative gram-negative rods Aeromonas, Plesiomonas, and Enterobacter agglomerans. Infection 10:293-298.[CrossRef][Medline]

---

Antimicrobial Agents and Chemotherapy, March 2002, p. 871-874, Vol. 46, No. 3
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.3.872-875.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

This article has been cited by other articles:

• Lemaire, S., Glupczynski, Y., Duval, V., Joris, B., Tulkens, P. M., Van Bambeke, F. (2009). Activities of Ceftobiprole and Other Cephalosporins against Extracellular and Intracellular (THP-1 Macrophages and Keratinocytes) Forms of Methicillin-Susceptible and Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 2289-2297 [Abstract] [Full Text]  
• Anderson, S. D, Gums, J. G (2008). Ceftobiprole: An Extended-Spectrum Anti-Methicillin-Resistant Staphylococcus aureus Cephalosporin. The Annals of Pharmacotherapy 42: 806-816 [Abstract] [Full Text]  
• Queenan, A. M., Shang, W., Kania, M., Page, M. G. P., Bush, K. (2007). Interactions of Ceftobiprole with {beta}-Lactamases from Molecular Classes A to D. Antimicrob. Agents Chemother. 51: 3089-3095 [Abstract] [Full Text]  
• Lodise, T. P. Jr., Pypstra, R., Kahn, J. B., Murthy, B. P., Kimko, H. C., Bush, K., Noel, G. J., Drusano, G. L. (2007). Probability of Target Attainment for Ceftobiprole as Derived from a Population Pharmacokinetic Analysis of 150 Subjects. Antimicrob. Agents Chemother. 51: 2378-2387 [Abstract] [Full Text]  
• Davies, T. A., Page, M. G. P., Shang, W., Andrew, T., Kania, M., Bush, K. (2007). Binding of Ceftobiprole and Comparators to the Penicillin-Binding Proteins of Escherichia coli, Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus pneumoniae. Antimicrob. Agents Chemother. 51: 2621-2624 [Abstract] [Full Text]  
• Goldstein, E. J. C., Citron, D. M., Merriam, C. V., Warren, Y. A., Tyrrell, K. L., Fernandez, H. T. (2006). In Vitro Activity of Ceftobiprole against Aerobic and Anaerobic Strains Isolated from Diabetic Foot Infections. Antimicrob. Agents Chemother. 50: 3959-3962 [Abstract] [Full Text]  
• Davies, T. A., Shang, W., Bush, K. (2006). Activities of Ceftobiprole and Other {beta}-Lactams against Streptococcus pneumoniae Clinical Isolates from the United States with Defined Substitutions in Penicillin-Binding Proteins PBP 1a, PBP 2b, and PBP 2x.. Antimicrob. Agents Chemother. 50: 2530-2532 [Abstract] [Full Text]  

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Zbinden, R. Articles by von Graevenitz, A. Search for Related Content PubMed PubMed Citation Articles by Zbinden, R. Articles by von Graevenitz, A.